Metachromatic Leukodystrophy (MLD) — Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)
Citation(s)
A Single Center, Open-label, Non-randomized, Uncontrolled, Multiple-dose, Dose Escalation Study of the Safety, Pharmacokinetics and Efficacy of Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)